| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 1,310 | 660 | 0 | 0 | 0 |
| Sales Growth | +98.48% | unch | unch | unch | unch |
| Net Income | -8,310 | 4,800 | -6,500 | -5,800 | -12,860 |
| Net Income Growth | -273.13% | +173.85% | -12.07% | +54.90% | -825.18% |
Scinai Immunotherapeutics Ltd ADR (SCNI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing inflammation and immunology biological products primarily for the treatment of autoimmune and infectious diseases. Scinai Immunotherapeutics Ltd., formerly known as BiondVax Pharmaceuticals Ltd., is based in JERUSALEM.
Fiscal Year End Date: 12/31